Clinical trials
Observational Neuromyelitis Optica trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
20 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2014 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 9 |
| Unknown status | 7 |
| Completed | 2 |
| Enrolling by invitation | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Beijing Tiantan Hospital | 4 |
| Tongji Hospital | 3 |
| Huashan Hospital | 2 |
| Third Affiliated Hospital, Sun Yat-Sen University | 2 |
| Xuanwu Hospital, Beijing | 2 |
| Alexion Pharmaceuticals, Inc. | 1 |
| Beijing Tongren Hospital | 1 |
| Chinese PLA General Hospital | 1 |
| First Affiliated Hospital of Fujian Medical University | 1 |
| Junwei Hao, MD | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neuromyelitis Optica | 20 |
| Multiple Sclerosis | 10 |
| Autoimmune Diseases of the Nervous System | 5 |
| Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease | 5 |
| Encephalomyelitis, Acute Disseminated | 4 |
| Myasthenia Gravis | 4 |
| Guillain-Barre Syndrome | 3 |
| Autoimmune Diseases | 2 |
| Demyelinating Diseases | 2 |
| Myositis | 2 |
Trials
Showing 1 to 20 of 20. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.